{"organizations": [], "uuid": "139f144b2bf3d686ad129dc008d1faaf3ff01686", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180202.html", "section_title": "Archive News &amp; Video for Friday, 02 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-merck-q4-non-gaap-earnings-per-sha/brief-merck-q4-non-gaap-earnings-per-share-0-98-idUSASB0C3R9", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck Q4 Non-Gaap Earnings Per Share $0.98", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.003, "site_type": "news", "published": "2018-02-02T20:02:00.000+02:00", "replies_count": 0, "uuid": "139f144b2bf3d686ad129dc008d1faaf3ff01686"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-merck-q4-non-gaap-earnings-per-sha/brief-merck-q4-non-gaap-earnings-per-share-0-98-idUSASB0C3R9", "ord_in_thread": 0, "title": "BRIEF-Merck Q4 Non-Gaap Earnings Per Share $0.98", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters) - merck & co inc", "sentiment": "neutral"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 2 (Reuters) - Merck & Co Inc:\n* MERCK ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS\n* SEES FY 2018 NON-GAAP EARNINGS PER SHARE $4.08 TO $4.23 * SEES FY 2018 GAAP EARNINGS PER SHARE $2.97 TO $3.12 * Q4 GAAP LOSS PER SHARE $0.32 * Q4 NON-GAAP EARNINGS PER SHARE $0.98 * FOURTH-QUARTER 2017 GAAP EPS REFLECTS A $2.6 BILLION PROVISIONAL CHARGE RELATED TO U.S. TAX LEGISLATION\n* Q4 EARNINGS PER SHARE VIEW $0.94, REVENUE VIEW $10.49 BILLION -- THOMSON REUTERS I/B/E/S\n* QTRLY KEYTRUDA SALES $1,297 MILLION VERSUS $483 MILLION REPORTED LAST YEAR\n* FOURTH-QUARTER 2017 WORLDWIDE SALES WERE $10.4 BILLION, AN INCREASE OF 3 PERCENT\n* FY2018 EARNINGS PER SHARE VIEW $4.11 -- THOMSON REUTERS I/B/E/S\n* ANTICIPATES FULL-YEAR 2018 WORLDWIDE SALES TO BE BETWEEN $41.2 BILLION AND $42.7 BILLION\n* FY2018 REVENUE VIEW $41.07 BILLION -- THOMSON REUTERS I/B/E/S\n* Q4 PHARMACEUTICAL SALES INCREASED 4 PERCENT TO $9.3 BILLION, INCLUDING A 1 PERCENT POSITIVE IMPACT FROM FOREIGN EXCHANGE\n* QTRLY REMICADE SALES $186 MILLION VERSUS $269 MILLION REPORTED LAST YEAR\n* MERCK - Q4 REVENUE UNFAVORABLY AFFECTED BY ABOUT $125 MILLION FROM LOST SALES IN SOME MARKETS RELATED TO JUNE CYBER-ATTACK\n* QTRLY JANUVIA/JANUMET SALES $1,524 MILLION VERSUS $1,509 MILLION REPORTED LAST YEAR\n* MERCK - PLANS TO INVEST ABOUT $12 BILLION OVER 5 YEARS IN CAPITAL PROJECTS INCLUDING ABOUT $8 BILLION IN THE U.S.\n* MERCK - PLANS TO PROVIDE ONE-TIME, LONG-TERM INCENTIVE AWARD FOR ELIGIBLE NON-EXECUTIVE EMPLOYEES IN Q2 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-02T20:02:00.000+02:00", "crawled": "2018-02-03T21:14:33.009+02:00", "highlightTitle": ""}